Summary
Abbott Laboratories (ABT) filed an 8-K on April 16, 2008, to report its first-quarter 2008 financial results. The report primarily furnishes a press release detailing these results, which were announced on April 15, 2008. Investors should note that Abbott utilizes non-GAAP financial measures, such as net earnings and diluted earnings per share excluding specified items, to provide a clearer view of ongoing business performance by adjusting for unusual or unpredictable factors like acquisition costs and R&D charges. The company's management believes these adjusted figures offer valuable insights for investors, allowing for a better evaluation of operational performance. However, the filing explicitly cautions investors to consider these non-GAAP measures alongside, and not as a replacement for, their GAAP-prepared financial statements. The primary exhibit referenced is the April 16, 2008 press release containing the detailed financial results.
Key Highlights
- 1Abbott Laboratories announced its first-quarter 2008 financial results via an 8-K filing.
- 2The filing includes a press release dated April 16, 2008, detailing the Q1 2008 performance.
- 3Abbott employed non-GAAP financial measures, such as earnings per share excluding specified items, in its results announcement.
- 4These non-GAAP measures are used to adjust for unusual or unpredictable factors, aiming to clarify ongoing business performance.
- 5Examples of adjustments include acquisition-related costs, cost reduction initiatives, and R&D charges.
- 6Management believes these adjusted measures provide useful insights for investors in evaluating business performance.
- 7Investors are cautioned to consider these non-GAAP measures in conjunction with, not as a substitute for, GAAP financials.